Start-Up Stadium Presentations Tuesday Morning

11:00 AM - 1:00 PM (EDT), Tuesday, June 6, 2023 ・ North Lobby
Start-Up Stadium is designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the world’s largest biotechnology partnering event. During the 2023 BIO International Convention select finalists from around the world will share a quick pitch showcasing new technologies and therapeutic solutions to a panel of investor judges, followed by live feedback.

This year will also feature evaluation of the presentations from seed-stage company finalists (less than $1M raised) separate from emerging company finalists (more than $1M but less than $10M raised to date). with a winner identified for each category. Past prizes have included 'fast-track' admission review to incubator programs at the Illumina Accelerator and The Innovation Space, as well as complimentary, one-year memberships in the Biotechnology Innovation Organization with access to the cost-savings programs of BIO Business Solutions.
11:00 AM - 1:00 PM
Gilboa is a preclinical-stage biopharmaceutical company, co-located in Boston and Israel, that is…
North Lobby
Asgard Therapeutics is a Swedish private biotech company advancing cancer immunotherapies by…
North Lobby
Genius owns self-invented ultrasonic & AI technologies and provides innovative medical devices,…
North Lobby
Swaza is developing the first nanofluid breathing aid to treat acute oxygen loss. Our vision is to…
North Lobby
Moleculex has created the world's first "intraoral" wound dressing to treat severe oral ulcers…
North Lobby
At Promakhos Therapeutics, we create therapies for autoinflammatory diseases based on a new and…
North Lobby
We, ARCE Therapeutics, Inc., specialize in developing first and best-in-class gene-modified…
North Lobby
Saros Therapeutics is developing an innate immune activation technology for oncology. While…
North Lobby
Ardan Pharma is an academic spin off company, investigating one guilty molecule of checkpoint…
North Lobby